Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2022
Reporting Period: First quarter ended March 31, 2022
Business Context: The filing serves as a notification of the announcement of financial results for the first quarter of 2022. The full details of the results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The filing states that the full text of the press release with financial results is attached as Exhibit 99.1. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. It only confirms the announcement of Q1 2022 results.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It references a press release (Exhibit 99.1) for the full announcement details. The filing includes a standard disclaimer that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 10, 2022) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing) and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol IDYA on The Nasdaq Global Select Market.
- Check for any subsequent filings that may incorporate the Q1 2022 results by reference.